

# CITATION REPORT

List of articles citing

Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma

DOI: 10.1016/j.oraloncology.2011.08.007  
Oral Oncology, 2011, 47, 1148-53.

**Source:** <https://exaly.com/paper-pdf/51088075/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
175	B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. <b>2013</b> , 7, 113-21		103
174	Effector CD4 and CD8 T cells and their role in the tumor microenvironment. <b>2013</b> , 6, 123-33		190
173	Promising systemic immunotherapies in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , <b>2013</b> , 49, 1089-96	4.4	85
172	Immune alterations and immunotherapy prospects in head and neck cancer. <b>2013</b> , 13, 1241-56		35
171	Effect of the premalignant and tumor microenvironment on immune cell cytokine production in head and neck cancer. <i>Cancers</i> , <b>2014</b> , 6, 756-70	6.6	35
170	[Recurrence of upper aerodigestive tract tumors]. <b>2014</b> , 101, 511-20		3
169	PD-1 blockage delays murine squamous cell carcinoma development. <b>2014</b> , 35, 424-31		29
168	Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. <b>2014</b> , 120, 624-32		39
167	Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 89, 140-65	7	122
166	The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. <b>2014</b> , 7, 1-17		72
165	PD-L1 expression in triple-negative breast cancer. <b>2014</b> , 2, 361-70		698
164	The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , <b>2014</b> , 50, 627-32	4.4	161
163	Tumor microenvironment in head and neck squamous cell carcinoma. <b>2014</b> , 41, 217-34		156
162	Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. <b>2015</b> , 20, 1247-52		26
161	Clinical relevance of immune parameters in the tumor microenvironment of head and neck cancers. <i>Head and Neck</i> , <b>2015</b> , 37, 449-59	4.2	39
160	Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. <i>Oral Oncology</i> , <b>2015</b> , 51, 221-8	4.4	218
159	Immunotherapy for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , <b>2015</b> , 51, 299-304	4.4	16

158	Immunity in head and neck cancer. <b>2015</b> , 3, 12-7		46
157	Evolving Concepts: Immunity in Oncology from Targets to Treatments. <b>2015</b> , 2015, 847383		20
156	High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. <b>2015</b> , 117, 165-70		36
155	Emerging drugs for head and neck cancer. <b>2015</b> , 20, 313-29		23
154	The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. <b>2015</b> , 19, 201-11		66
153	Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer: Review of current data. <i>Oral Oncology</i> , <b>2015</b> , 51, 12-5	4.4	43
152	Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC). <i>Cancers</i> , <b>2016</b> , 8,	6.6	37
151	The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. <b>2016</b> , 4, 173		61
150	Immune Checkpoint Therapy in Head and Neck Cancers. <b>2016</b> , 22, 108-16		10
149	The Unfolded Protein Response as a Therapeutic Target for Head and Neck Squamous Cell Carcinoma. <b>2016</b> , 225-261		2
148	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. <i>Oral Oncology</i> , <b>2016</b> , 61, 152-8	4.4	40
147	Pembrolizumab: the value of PDL1 biomarker in head and neck cancer. <b>2016</b> , 16, 1075-8		11
146	Circulating tumor cells in head and neck cancer: A review. <b>2016</b> , 2, 109-116		13
145	Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells. <b>2016</b> , 7, 538-43		7
144	HNSCC Biomarkers Derived from Key Processes of Cancerogenesis. <b>2016</b> , 115-160		1
143	Immunotherapy for Head and Neck Squamous Cell Carcinoma. <b>2016</b> , 3, 74-81		6
142	Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. <b>2016</b> , 43, 113-23		8
141	[Current events in immunotherapy for upper aerodigestive tract cancer]. <b>2017</b> , 37, 79-89		7

140	Chromosomal Alterations and Gene Expression Changes Associated with the Progression of Leukoplakia to Advanced Gingivobuccal Cancer. <b>2017</b> , 10, 396-409		36
139	Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. <b>2017</b> , 96, e6369		113
138	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , <b>2017</b> , 70, 34-42	4.4	29
137	Immunotherapy for head and neck cancer: the future of treatment?. <b>2017</b> , 17, 701-708		19
136	Tumor-like microenvironment in oral lichen planus: evidence of malignant transformation?. <b>2017</b> , 13, 635-643		19
135	Radiotherapy plus EGFR inhibitors: synergistic modalities. <b>2017</b> , 2, 2		3
134	TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?. <b>2017</b> , 11, 354-363		39
133	Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , <b>2017</b> , 123, e188-e196	2	17
132	Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice. <b>2017</b> , 292, 20657-20668		31
131	GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC. <i>Oncolmmunology</i> , <b>2017</b> , 6, e1353860	7.2	18
130	Circulating tumour cell PD-L1 test for head and neck cancers. <i>Oral Oncology</i> , <b>2017</b> , 75, 6-7	4.4	10
129	Checkpoint immunotherapy in head and neck cancers. <b>2017</b> , 36, 475-489		27
128	Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. <b>2017</b> , 43, 1602-1612		48
127	PD-1/PD-L1 biology and immunotherapy in HPV-positive oral cancers. <b>2017</b> , 13, 1907-1909		2
126	Immunohistochemical investigations on the expression of programmed cell death ligand 1, human leukocyte antigens G and E, and granzyme B in intraoral mucoepidermoid carcinoma. <i>Archives of Oral Biology</i> , <b>2017</b> , 83, 55-62	2.8	15
125	Oral Cancer Stem Cells Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , <b>2017</b> , 1041, 207-233	3.6	9
124	Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study. <b>2017</b> , 75, 969-977		25
123	PD-L1 expression is associated with p16 expression in non-oropharyngeal head and neck squamous cell carcinoma. <b>2018</b> , 15, 2259-2265		9

122	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. <b>2017</b> , 11, 2537-2549		4
121	PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 52889-52900	3.3	64
120	High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. <b>2017</b> , 13, 1172-1179		30
119	Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma. <b>2017</b> , 10, 5745-5754		6
118	Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. <b>2017</b> , 8, 332-344		17
117	Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics. <i>Oncotarget</i> , <b>2017</b> , 8, 19310-19322	3.3	66
116	Density and location of CD3 and CD8 tumor-infiltrating lymphocytes correlate with prognosis of oral squamous cell carcinoma. <b>2018</b> , 47, 359-367		28
115	Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. <b>2018</b> , 65, 54-64		40
114	Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition. <b>2018</b> , 80, 28-39		14
113	Rescue of iCIKs transfer from PD-1/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC). <b>2018</b> , 59, 127-133		5
112	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. <b>2018</b> , 52, 228-240		162
111	Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. <b>2018</b> , 47, 836-845		46
110	A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. <b>2018</b> , 17, 710-716		20
109	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. <b>2018</b> , 3, e000257		40
108	Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors. <b>2018</b> , 78, 249-261		81
107	Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody LMab-4. <b>2018</b> , 13, 123-128		3
106	AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. <i>Head and Neck</i> , <b>2018</b> , 40, 676-686	4.2	10
105	PD-1 and cancer: molecular mechanisms and polymorphisms. <b>2018</b> , 70, 73-86		62

104	HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers. <b>2018</b> , 16, 90-102		91
103	Can We Expect Less Toxicities with Newer Forms of Radiotherapy?. <b>2018</b> , 181-212		
102	Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , <b>2018</b> , 86, 278-287	4.4	23
101	The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. <i>Oral Oncology</i> , <b>2018</b> , 86, 81-90	4.4	69
100	Head and Neck Tumors. <b>2018</b> , 1-136		1
99	Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types. <b>2018</b> , 82, 131-139		34
98	PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2019</b> , 160, 93-99	5.5	13
97	Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis. <b>2019</b> , 11, 501-522		16
96	The prognostic role of tumour-infiltrating lymphocytes in oral squamous cell carcinoma: A meta-analysis. <b>2019</b> , 48, 788-798		21
95	Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma. <b>2019</b> , 19, 1022		6
94	Association of PD-L1 expression in oral squamous cell carcinoma with smoking, sex, and p53 expression. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , <b>2019</b> , 128, 631-638	2	8
93	Impact of HPV Infection on the Immune System in Oropharyngeal and Non-Oropharyngeal Squamous Cell Carcinoma: A Systematic Review. <b>2019</b> , 8,		16
92	Head and Neck Tumors. <b>2019</b> , 627-762		
91	Clinical relevance and significance of programmed death-ligand 1 expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 4335-4345	3.6	16
90	PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. <b>2019</b> , 17, 207		10
89	Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. <b>2019</b> , 2019, 2532518		7
88	PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma. <b>2019</b> , 60, 2388-2398		20
87	Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray. <b>2019</b> , 17, 32-39		10

86	The Double-Edged Sword-How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 653	8.4	25
85	Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer. <b>2019</b> , 47, 1036-1042		7
84	Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes. <i>Pathology Research and Practice</i> , <b>2019</b> , 215, 152418	3.4	17
83	Tissue-infiltrating immune cells as prognostic markers in oral squamous cell carcinoma: a systematic review and meta-analysis. <b>2019</b> , 120, 714-727		42
82	Cancers of the Head and Neck. <b>2019</b> , 103-114		
81	High Density of Intratumor CD45RO Memory Tumor-Infiltrating Lymphocytes Predicts Favorable Prognosis in Patients With Oral Squamous Cell Carcinoma. <b>2019</b> , 77, 536-545		10
80	Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. <i>Oral Oncology</i> , <b>2019</b> , 88, 95-101	4.4	29
79	High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature. <b>2019</b> , 52, e12537		30
78	Tumor-infiltrating CD8 T-cell density is an independent prognostic marker for oral squamous cell carcinoma. <b>2019</b> , 8, 80-93		60
77	The prognostic value of immune checkpoints in oral squamous cell carcinoma. <i>Oral Diseases</i> , <b>2019</b> , 25, 1435-1445	3.5	21
76	PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma. <b>2019</b> , 28, 546-554		31
75	Reduced CD8 T cells infiltration can be associated to a malignant transformation in potentially malignant oral epithelial lesions. <i>Clinical Oral Investigations</i> , <b>2019</b> , 23, 1913-1919	4.2	17
74	Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study. <i>Archives of Oral Biology</i> , <b>2019</b> , 98, 99-107	2.8	8
73	An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives. <i>Oral Diseases</i> , <b>2020</b> , 26, 511-526	3.5	24
72	Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , <b>2020</b> , 102, 104560	4.4	9
71	The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis. <i>Pathology Research and Practice</i> , <b>2020</b> , 216, 152768	3.4	12
70	Digital Image Analysis of CD8+ and CD3+ Tumor-Infiltrating Lymphocytes in Tongue Squamous Cell Carcinoma. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 8275-8285	3.6	6
69	Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis. <i>Archives of Oral Biology</i> , <b>2020</b> , 119, 104916	2.8	1

68	The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1721	8.4	23
67	Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. <i>Frontiers in Cell and Developmental Biology</i> , <b>2020</b> , 8, 758	5.7	39
66	Immune Checkpoint Inhibitors in Oral Cavity Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review. <i>Cancers</i> , <b>2020</b> , 12,	6.6	24
65	Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis. <i>BMC Clinical Pathology</i> , <b>2020</b> , 13, 2632010X20964846	1.3	1
64	The role of vitamin D in head and neck cancer. <i>Laryngoscope Investigative Otolaryngology</i> , <b>2020</b> , 5, 1079-1088	1.8	1
63	PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma. <i>Oncolimmunology</i> , <b>2020</b> , 9, 1844403	7.2	5
62	Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy. <i>Current Opinion in Immunology</i> , <b>2020</b> , 64, 80-87	7.8	32
61	PD-L1 in squamous cell carcinoma of the oral tongue shows gender-specific association with prognosis. <i>Oral Diseases</i> , <b>2020</b> , 26, 1414-1423	3.5	3
60	The promise of immunotherapy in the treatment of young adults with oral tongue cancer. <i>Laryngoscope Investigative Otolaryngology</i> , <b>2020</b> , 5, 235-242	2.8	2
59	Tumor immune microenvironment in head and neck cancers. <i>Molecular Carcinogenesis</i> , <b>2020</b> , 59, 766-774	5.5	29
58	Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. <i>Oral Oncology</i> , <b>2020</b> , 106, 104722	4.4	30
57	PD-L1 and LAG-3 expression in advanced cutaneous squamous cell carcinomas. <i>Journal of Cutaneous Pathology</i> , <b>2020</b> , 47, 882-887	1.7	5
56	Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis. <i>Archives of Oral Biology</i> , <b>2020</b> , 114, 104717	2.8	7
55	Clinical significance of tumor-associated immune cells in patients with oral squamous cell carcinoma. <i>Head and Neck</i> , <b>2021</b> , 43, 534-543	4.2	2
54	Association Between Immunosuppression and Outcomes in Oral Cavity Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2021</b> , 164, 1044-1051	5.5	2
53	, as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration. <i>Oncolimmunology</i> , <b>2021</b> , 10, 1938890	7.2	5
52	GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer. <i>Oncology Reports</i> , <b>2021</b> , 45, 997-1010	3.5	1
51	PD-L1 expression in recurrent head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2021</b> , 1	3.5	2



50	Low PDL1 Expression in Tumour Infiltrating Lymphocytes Predicts Local Recurrence in Oral Squamous Cell Carcinoma. <i>Indian Journal of Surgical Oncology</i> , <b>2021</b> , 12, 408-414	0.7	0
49	Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
48	Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	2
47	Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancer. <i>Scientific Reports</i> , <b>2021</b> , 11, 14064	4.9	1
46	CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , <b>2021</b> , 132, 202-209	2	4
45	Epigenetic modulation of the tumor microenvironment in head and neck cancer: Challenges and opportunities. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 164, 103397	7	2
44	Immunosuppressive microenvironment in oral cancer: implications for cancer immunotherapy. <i>Exploration of Immunology</i> ,		
43	Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 705614	5.3	5
42	High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	2
41	Chemotherapy in Head and Neck Squamous Cell Cancer. <b>2016</b> , 53-68		1
40	PD-L1 and Survival in Solid Tumors: A Meta-Analysis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0131403	3.7	235
39	Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0179536	3.7	25
38	Metastatic disease in head & neck oncology. <i>Acta Otorhinolaryngologica Italica</i> , <b>2020</b> , 40, S1-S86	2.8	27
37	Clinicopathological Features of Programmed Cell Death-ligand 1 Expression in Patients with Oral Squamous Cell Carcinoma. <i>Open Medicine (Poland)</i> , <b>2020</b> , 15, 292-301	2.2	2
36	CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 71455-71465	3.3	34
35	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. <i>Oncotarget</i> , <b>2017</b> , 8, 14416-14427	3.3	54
34	Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 66178-66194	3.3	42
33	PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 112584-112597	3.3	25

32	Prognostic value of PD -L1 expression in patients with primary solid tumors. <i>Oncotarget</i> , <b>2018</b> , 9, 5058-5072	3.2	35
31	Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype. <i>Oncotarget</i> , <b>2018</b> , 9, 11126-11144	3.3	5
30	Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. <i>Oncotarget</i> , <b>2015</b> , 6, 11139-49	3.3	72
29	Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. <i>Oncotarget</i> , <b>2015</b> , 6, 20902-20	3.3	75
28	CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. <i>Oncotarget</i> , <b>2016</b> , 7, 12024-34	3.3	112
27	Comparison of Squamous Cell Carcinoma of the Tongue between Young and Old Patients. <i>Journal of Pathology and Translational Medicine</i> , <b>2019</b> , 53, 369-377	2.9	3
26	Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , <b>2016</b> , 48, 527-36	5.2	90
25	Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. <i>ELife</i> , <b>2020</b> , 9,	8.9	48
24	Recent Updates in Cancer Immunotherapy. <i>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</i> , <b>2015</b> , 58, 449	0.2	1
23	OPTIMAL TREATMENT STRATEGY FOR PATIENTS WITH PROGRESSIVE SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. <i>Issledovanĭi Praktika V Medicene</i> , <b>2019</b> , 6, 115-128	0.4	
22	PD-L1 and CD8-Tumor-Infiltrating Lymphocytes Expression in Laryngeal Squamous Cell Carcinoma. <i>ARS Medica Tomitana</i> , <b>2020</b> , 26, 137-144	0.2	
21	The Microenvironment of Tongue Cancer. <i>Advances in Experimental Medicine and Biology</i> , <b>2020</b> , 1296, 49-78	3.6	0
20	PD-L1 expression in colon cancer and its relationship with clinical prognosis. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2019</b> , 12, 1764-1769	1.4	20
19	[Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications]. <i>Hua Xi Kou Qiang Yi Xue Za Zhi = Huaxi Kouqiang Yixue Zazhi = West China Journal of Stomatology</i> , <b>2015</b> , 33, 529-33		8
18	[Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma]. <i>Hua Xi Kou Qiang Yi Xue Za Zhi = Huaxi Kouqiang Yixue Zazhi = West China Journal of Stomatology</i> , <b>2020</b> , 38, 449-453		1
17	Expression of PD-L1 and CD4+ tumor-infiltrating lymphocytes predict survival in head and neck squamous cell carcinoma.. <i>Molecular and Clinical Oncology</i> , <b>2022</b> , 16, 59	1.6	0
16	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.. <i>Molecular Diagnosis and Therapy</i> , <b>2022</b> , 1	4.5	
15	PD-L1 Expression Correlated with Clinicopathological Factors and Akt/Stat3 Pathway in Oral SCC.. <i>Life</i> , <b>2022</b> , 12,	3	1

14	Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma.. <i>Journal of Applied Oral Science</i> , <b>2022</b> , 30, e20210344	3.3	
13	Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies.. <i>Frontiers in Cell and Developmental Biology</i> , <b>2022</b> , 10, 830208	5.7	1
12	Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study.. <i>Biomedicines</i> , <b>2022</b> , 10,	4.8	1
11	Magnetic Resonance Imaging-Based Radiomics Features Associated with Depth of Invasion Predicted Lymph Node Metastasis and Prognosis in Tongue Cancer. <i>Journal of Magnetic Resonance Imaging</i> , <b>2021</b> ,	5.6	2
10	The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma. <i>Pathology Research and Practice</i> , <b>2022</b> , 153934	3.4	0
9	PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside.. <i>Clinical and Experimental Dental Research</i> , <b>2022</b> ,	1.9	1
8	Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma. <i>PLoS ONE</i> , <b>2022</b> , 17, e0269136	3.7	1
7	Expression of PD-L1 is HPV/P16-Independent in Oral Squamous Cell Carcinoma. <i>SSRN Electronic Journal</i> ,	1	
6	Laryngeal Leukoplakia: A Focus on Histology.		
5	Immune Cells in Head-and-Neck Tumor Microenvironments. <b>2022</b> , 12, 1521		1
4	Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma. <b>2022</b> , 8, e10667		0
3	Canine oral squamous cell carcinoma as a spontaneous, translational model for radiation and immunology research. 12,		0
2	High PD-L1 expression associates with low T-cadherin expression and poor prognosis in human papillomavirus-negative head and neck squamous cell carcinoma. <b>2023</b> , 45, 1162-1171		0
1	Tumor Microenvironment and Immune Response in Lip Cancer. <b>2023</b> , 15, 1478		0